IXICO has announced its interim results for the 6-months to March 2021. In-line with the trading update, revenues grew 8% to £4.9m in the period, the order book remained strong with new contract wins of £9.4m in the period and period end cash of £7.0m. Through the half, margins improved and EBITDA grew by c30% YoY. While we note the near-term impact of the descoped HD trials, we believe IXICO is well positioned to deliver growth in the mid to long term. The company continues to invest in R&D and ....
25 May 2021
Cenkos: IXICO Plc -- FY21 interims
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cenkos: IXICO Plc -- FY21 interims
IXICO Plc (IXI:LON) | 8.8 0 0.0% | Mkt Cap: 4.23m
- Published:
25 May 2021 -
Author:
Chris Donnellan -
Pages:
6
IXICO has announced its interim results for the 6-months to March 2021. In-line with the trading update, revenues grew 8% to £4.9m in the period, the order book remained strong with new contract wins of £9.4m in the period and period end cash of £7.0m. Through the half, margins improved and EBITDA grew by c30% YoY. While we note the near-term impact of the descoped HD trials, we believe IXICO is well positioned to deliver growth in the mid to long term. The company continues to invest in R&D and ....